Helus Pharma (NASDAQ: HELP) (Cboe CA: HELP), a clinical-stage pharmaceutical company developing novel serotonergic agonists (NSAs), has issued a correction to its April 28, 2026 press release regarding its partnership with TARA Mind. The correction removes references to Veterans Exploring Treatment Solutions from earlier paragraphs but reaffirms the collaboration’s alignment with a recent executive order aimed at advancing mental health treatments and clinical research participation.
The partnership is designed to support Phase 3 recruitment for Helus Pharma’s HLP003 program in major depressive disorder and expand outreach in veteran communities. HLP003, a proprietary NSA, is currently in Phase 3 clinical development for the adjunctive treatment of major depressive disorder and has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration. This designation underscores the potential of HLP003 to address significant unmet needs in mental health.
Helus Pharma, the commercial operating name of Cybin Inc., founded in 2019, is dedicated to developing proprietary NSAs—synthetic molecules designed to activate serotonin pathways believed to promote neuroplasticity. The company aims to address the large unmet need for people suffering from depression, anxiety, and other mental health conditions. With class-leading data, Helus Pharma seeks to improve the treatment landscape through NSAs that provide durable improvements in mental health.
In addition to HLP003, the company is developing HLP004, another proprietary NSA in Phase 2 for generalized anxiety disorder. Helus Pharma also maintains an extensive research portfolio of investigational NSAs. The company operates in Canada, the United States, the United Kingdom, and Ireland.
The correction to the partnership announcement is significant because it clarifies the scope of the collaboration while reaffirming its strategic importance. The alignment with a recent executive order on mental health treatments indicates that the partnership may benefit from federal support to accelerate clinical research and expand access to innovative therapies. For veterans and others suffering from major depressive disorder, this could mean faster development and availability of new treatment options.
Investors and industry observers should note that Helus Pharma’s focus on NSAs and its partnerships are central to its strategy to address mental health conditions. The Breakthrough Therapy Designation for HLP003 highlights the potential for this drug to become a key treatment option. The correction ensures that stakeholders have accurate information about the partnership’s scope, avoiding confusion that could impact investment decisions.
For more information, visit the full press release at https://ibn.fm/re8HL. Company updates are available at www.helus.com or by following Helus Pharma on X, LinkedIn, YouTube, and Instagram.
